Kornitzer Capital Management Inc Incyte Corp Transaction History

Kornitzer Capital Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 30, 2020	SELL	$85.07 - $109.69 $13.1 Million - $16.9 Million	-153,868 Closed	0 $0
Q2 2020 Aug 03, 2020	SELL	$74.18 - $108.93 $3.56 Million - $5.23 Million	-48,034 Reduced 23.79%	153,868 $16 Million
Q1 2020 Apr 30, 2020	SELL	$63.18 - $85.97 $36,454 - $49,604	-577 Reduced 0.28%	201,902 $14.8 Million
Q4 2019 Jan 31, 2020	BUY	$73.04 - $95.72 $1.54 Million - $2.02 Million	21,151 Added 11.66%	202,479 $17.7 Million
Q3 2019 Nov 04, 2019	SELL	$72.82 - $86.52 $102,093 - $121,301	-1,402 Reduced 0.77%	181,328 $13.5 Million
Q2 2019 Jul 31, 2019	BUY	$73.52 - $88.7 $367,600 - $443,500	5,000 Added 2.81%	182,730 $15.5 Million
Q1 2019 May 01, 2019	BUY	$63.56 - $88.17 $11.3 Million - $15.7 Million	177,730 New	177,730 $15.3 Million

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Kornitzer Capital Management Inc , based on Form 13F filings with the SEC.

Stay updated on Kornitzer Capital Management Inc with notifications on news.